Published: March 27, 2020

Introduction {#sec1}
============

Natural products produced by modular polyketide synthases (PKSs) have demonstrated their use as therapeutics, industrial products, pesticides, and biological probes following intense study over the past decades ([@bib12], [@bib22]). Some well-known examples of these polyketides include the antibiotic erythromycin and the immunosuppressant rapamycin, both of which were initially isolated from bacterial sources and have been approved for clinical use for decades ([@bib5], [@bib12], [@bib14]). The process for discovery, diversification, and mode of action elucidation of polyketides remains challenging and time consuming, although it has been improved in recent years due to many technical advancements. One such technology is to tag polyketides with a clickable functionality, which has been demonstrated to facilitate the study of polyketide biosynthesis, biology, and pharmacology through bio-orthogonal chemistry ([@bib6], [@bib11], [@bib13], [@bib16], [@bib17], [@bib24], [@bib33], [@bib38], [@bib40], [@bib57]). In particular, polyketides can be tagged through semi-synthesis ([@bib6], [@bib40]), total synthesis ([@bib42]), precursor-directed biosynthesis ([@bib11], [@bib24], [@bib33], [@bib41], [@bib49]), or *de novo* biosynthesis ([@bib54], [@bib57]). In this work we aim to further develop the strategy of *de novo* biosynthesis, which offers the unique advantage of not feeding the biorthogonal moiety itself, which could lead to increased background due to the diffusible non-specific nature of feeding starter or extender units. Instead the taggable group is incorporated by enzymatically synthesizing both the complex polyketide scaffolds and the unique clickable functionality allowing *in situ* bio-orthogonal chemical transformations.

Modular PKSs, often referred to as type I PKSs, have modules with multiple catalytic domains that perform separate enzymatic activities and act as an assembly line to select and incorporate building monomers into polyketide scaffolds ([@bib15], [@bib20], [@bib21], [@bib25]) ([Figure 1](#fig1){ref-type="fig"}). The monomers used for extension, typically malonyl- or methylmalonyl-CoA, are recognized by acyltransferase (AT) domains, and the carbon-carbon bond is formed through decarboxylative Claisen condensations catalyzed by the ketosynthase (KS) domains. The megasynthases themselves have been investigated and have undergone extensive engineering efforts due to their modular structures that have captured scientists\' imagination with the possibility of producing on-demand, designer molecules ([@bib1], [@bib2], [@bib4], [@bib11], [@bib18], [@bib22], [@bib24], [@bib32], [@bib36], [@bib44], [@bib45], [@bib48], [@bib50], [@bib51]). Many of these engineering strategies have included efforts geared toward the inclusion of functional chemical handles for subsequent drug discovery or chemical biology studies, albeit often employing fed precursors containing the functionality of interest ([@bib16], [@bib24], [@bib30]).Figure 1Overview of the JamABC Cassette and Type I PKSs in This Work(A) JamABC works together to produce 5-hexynoyl-JamC as a starter unit for the downstream PKS/nonribosomal peptide synthetase assembly line in jamaicamide B biosynthesis.(B) Native LipPKS1 and DEBSM6 domain organization and associated polyketide products.(C) Engineered LipPKS1^∗^ and DEBSM6^∗^ used as representative modular PKSs in the current study.

The terminal alkyne is a canonical bio-orthogonal functional group as it is small, stable, and can be selectively reacted via copper-catalyzed azide-alkyne cycloaddition, where an azide containing a fluorophore, mass tag, or other chemical moiety is attached ([@bib35], [@bib57]). The bio-orthogonality of alkynes is due to its chemical stability in biological environments and its rarity in biology where only a small number of terminal alkyne-bearing secondary metabolites have been discovered and even fewer biosynthetic pathways have been elucidated ([@bib7], [@bib8], [@bib10], [@bib26], [@bib27], [@bib28], [@bib29], [@bib31], [@bib39]). We recently identified and characterized an acyl carrier protein (ACP)-dependent, three-protein pathway to generate the terminal alkyne functionality in *E. coli* ([@bib54], [@bib56], [@bib55]). For example, in the biosynthesis of the cyanobacterial jamaicamide B, JamA, an acyl-ACP synthetase, activates and loads 5-hexanoic acid onto JamC, a dedicated ACP. The resulting 5-hexanoyl-JamC is modified by JamB, a membrane-bound desaturase/acetylenase, to yield 5-hexynoyl-JamC as a starter unit for the downstream PKS/nonribosomal peptide synthetase assembly line ([Figure 1](#fig1){ref-type="fig"}A) ([@bib7], [@bib54]). *JamABC* thus represents a portable tri-gene cassette that may be useful for *in situ* generation and incorporation of terminal alkynes into various molecular scaffolds on demand. Toward this end, we demonstrated that PKS starter unit engineering is a feasible strategy to install the fatty alkynyl starter unit generated by JamABC onto polyketide scaffolds, such as those generated by promiscuous type III PKSs, which recognize both the acyl group and the acyl carrier (JamC) ([@bib54], [@bib56]). However, to generalize this strategy to other polyketide scaffolds, in particular those synthesized by modular type I PKSs, additional model systems and protein engineering methods need to be explored.

Here we employ two well-studied type I PKSs, LipPKS1 and DEBSM6, to explore engineering strategies to make alkyne-tagged polyketides. LipPKS1 is the first module in lipomycin biosynthesis that natively utilizes an isobutyl starter unit presented by a loading ACP ([Figure 1](#fig1){ref-type="fig"}B) ([@bib3]). DEBSM6 is the last PKS module from the erythromycin biosynthetic pathway ([Figure 1](#fig1){ref-type="fig"}B) ([@bib37]). In addition, engineered LipPKS1 and DEBSM6 have been obtained to utilize malonyl-CoA instead of methylmalonyl-CoA as the extender unit with the promiscuous DEBS thioesterase to promote the acid product release as demonstrated from both *in vitro* biochemical studies and in *E. coli* ([@bib51]). These two engineered modules are thus simple and convenient systems for in-depth assessment of the interaction between representative module PKSs and JamABC for alkyne-tagged polyketide biosynthesis. Considering the known critical role of the cognate ACP (JamC) in the alkyne biosynthetic machinery ([@bib43], [@bib54]), the recognition of JamC by PKSs is expected to play a key role in alkyne-tagged polyketide synthesis and therefore is the focus of the present study.

Results and Discussion {#sec2}
======================

Alkyne-Tagged Polyketide Synthesis *In Vitro* {#sec2.1}
---------------------------------------------

To probe the possible recognition of the 5-hexynoyl-JamC by PKSs, *in vitro* assays were initially performed using the engineered LipPKS1 and DEBSM6 modules. The reported engineered LipPKS1 was further modified by removing the AT and ACP loading domains to create a truncated version to facilitate the alternative starter unit incorporation. We hypothesized that these engineered PKSs (termed LipPKS1∗ and DEBSM6∗, [Figure 1](#fig1){ref-type="fig"}C) without the loading domains would result in JamC to act in *trans* to selectively load and extend JamC-linked acyl chains. For *in vitro* assessment we purified JamA, holo-JamC, and LipPKS1∗/DEBSM6∗ from *E. coli* after overexpression ([Figure S1](#mmc1){ref-type="supplementary-material"}), or an *E. coli* BAP1 strain that contains a chromosomal copy of the phosphopantetheinyl transferase Sfp that was used to ensure the post-translational modification of carrier proteins to the pantetheinylated forms ([@bib34]). Purified enzymes were incubated with 5-hexynoic acid, ATP, malonyl-CoA, and NADPH for alkyne-tagged polyketide biosynthesis *in vitro* ([Figure 2](#fig2){ref-type="fig"}A). JamB activity for alkyne biosynthesis was not assessed *in vitro* due to the difficulty of obtaining active and purified membrane proteins and was assessed later *in vivo*. The expected product, 3-hydroxy-7-octynoic acid (**1**), was successfully produced by both engineered PKSs as confirmed by comparing with the synthetic chemical standard ([Figures 2](#fig2){ref-type="fig"}B, 2C, and [S2--S4](#mmc1){ref-type="supplementary-material"}, [Scheme S1](#mmc1){ref-type="supplementary-material"}). Interestingly, replacement of 5-hexynoyl-JamC by 5-hexynoyl-CoA, which was generated *in situ* using a promiscuous acyl-CoA ligase Orf35 ([@bib53]), dropped the formation of **1** to trace amounts, demonstrating a preference of these two PKSs toward JamC over CoA as the acyl carrier ([Figures 2](#fig2){ref-type="fig"}B, 2C, and [S2](#mmc1){ref-type="supplementary-material"}).Figure 2*In Vitro* Assessment of Alkyne-Tagged Polyketide Biosynthesis Using LipPKS1∗ and DEBSM6∗(A) Overview scheme of *in vitro* reactions between JamA/JamC and engineered PKSs to produce 3-hydroxy-7-octynoic acid (**1**).(B) Formation of **1** by LipPKS1^∗^ under various reaction conditions and engineering strategies.(C) Formation of **1** by DEBSM6^∗^ under various reaction conditions and engineering strategies. Engineered PKS cartoon is truncated for clarity. All graphs are shown as relative product formed compared with the JamC/PKS with no modifications calculated from integration of the extracted ion chromatogram (EIC) for compound **1** (set as 1). Error bars indicate SEM for n ≥ 2 independent experiments.

Evaluation of Docking Domain Strategy to Improve JamC-PKS Interactions {#sec2.2}
----------------------------------------------------------------------

As protein-protein interactions are known to dominate the turnover of chimeric PKS assembly lines ([@bib23]), we proposed that improved communication between the upstream JamC and the downstream KS could lead to a more efficient alkyne-tagged polyketide biosynthesis. Docking domains, often found on the C terminus of ACPs (dd^ACP^) and the N terminus of KSs (dd^KS^), have been shown to be important for protein-protein interactions in PKSs ([@bib9], [@bib46], [@bib52]). We then set out to evaluate the strategy of fusing known docking domains to the C terminus of JamC and the N terminus of the LipPKS1∗/DEBSM6∗ KS domains to improve protein recognition. In particular, we chose to utilize the class 2 docking domains from the cyanobacterial curacin pathway as the pair ~C~dd^CurK^ (dd^ACP^) and ~N~dd^CurL^(dd^KS^) was shown to be modular and portable ([@bib47]). We also chose the related docking domain pair ~C~dd^JamK^ (dd^ACP^) and ~N~dd^JamL^(dd^KS^) from the jamaicamide pathway as moving docking domains within pathways was shown to be more successful than inter-pathway swapping ([@bib22], [@bib23], [@bib47]). The fusion of these docking domains to JamC and PKSs did not significantly impact the expression and folding of these proteins ([Figures S1](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}). *In vitro* product formation assays using purified proteins demonstrated the success of this strategy in generating product **1** ([Figures 2](#fig2){ref-type="fig"} and [S6](#mmc1){ref-type="supplementary-material"}). The adoption of the pair of ~C~dd^JamK^ and ~N~dd^JamL^ had minimal effect on the production of **1**, whereas the pair of ~C~dd^CurK^ and ~N~dd^CurL^ led to significantly more amount of **1** in both PKS systems (∼3-fold for LipPKS1∗ and ∼40-fold for DEBSM6∗) ([Figures 2](#fig2){ref-type="fig"}B and 2C). Control experiments using only one of the docking domains produced less products than using the pair for ~C~dd^CurK^ and ~N~dd^CurL^. In addition, the poor production of **1** with the docking domain fused to JamC excluded the possibility of improved recognition of modified JamC by JamA ([Figures 2](#fig2){ref-type="fig"}B and 2C), indicating that the improved communication between the engineered JamC and KS due to the docking domains is the main contributor for higher production of **1** *in vitro*.

Evaluation of Site-Directed Mutagenesis of JamC to Improve JamC-PKS Interactions {#sec2.3}
--------------------------------------------------------------------------------

In addition to docking domains, we also wanted to identify a less-intensive engineering strategy to improve JamC-PKS communication. Mutating JamC without perturbation to the large megasynthase would make this strategy more easily adaptable to different systems. From the well-studied DEBS system, it has been shown that direct ACP-KS protein-protein interactions during translocation are selective, and key residues within helix I of ACP have been identified that contribute to chain translocation specificity ([@bib19], [@bib23]). Inspired by the previous successful studies, we identified the corresponding residue in JamC (E32) that may play an important role in ACP-KS interactions through sequence alignments and structural modeling ([Figure S7](#mmc1){ref-type="supplementary-material"}). To mimic the native upstream ACP, we chose the mutations E32T for LipPKS1∗ and E32H for DEBSM6∗ based on alignments to the respective ACPs found upstream in the native systems ([Figure S7](#mmc1){ref-type="supplementary-material"}). These two JamC mutants were cloned, overexpressed, and purified from BAP1 with a similar yield to the wild-type protein ([Figure S1](#mmc1){ref-type="supplementary-material"}). *In vitro* product formation assays showed that the formation of **1** increased approximately 7-fold with LipPKS1∗ ([Figure 2](#fig2){ref-type="fig"}B) and 2-fold with DEBSM6∗ ([Figure 2](#fig2){ref-type="fig"}C). These fold increases demonstrated the effectiveness of this strategy in improving the production of alkyne-tagged polyketides *in vitro*, most likely due to an improved JamC communication with modular PKSs.

Perturbation of JamB Activity by JamC Engineering {#sec2.4}
-------------------------------------------------

*In vitro* biochemical assays demonstrated the success of protein engineering in improving the recognition of JamC by PKSs to promote the translocation of the alkynyl starter unit. However, the potential impact of JamC modification on the activity of JamB, the desaturase/acetylenase that functions on a JamC-tethered substrate to form a terminal alkyne, is unclear. As it is difficult to reconstitute and quantify the activity of the membrane-bound JamB *in vitro*, we then tried to implement the biosynthetic machinery of alkyne-tagged polyketides in *E. coli* to assess the possible impact. In addition, the titers of relevant products were also quantified in *E. coli* to probe the effectiveness of two engineering strategies to improve JamC-PKS interactions *in vivo*. Combinations of JamA, B, C, PKSs, and their variants were expressed in an *E. coli* BAP1 strain under a T7 promoter to obtain various engineered strains. A single mutation in JamB (M5T) identified in previous work, presumably with an improved interaction with the electron donor, was used in all strains to increase the alkyne titer in *E. coli* ([@bib55]). All strains were grown with 5-hexenoic acid feeding, followed by extraction and quantification of 3-hydroxy-7-octenoic acid (**2**) and 3-hydroxy-7-octynoic acid production (**1**), by fitting to a standard curve of synthesized standards generated through liquid chromatography-high-resolution mass spectrometric analysis ([Scheme S1](#mmc1){ref-type="supplementary-material"}, [Figures S3](#mmc1){ref-type="supplementary-material"}, [S4](#mmc1){ref-type="supplementary-material"}, [S8](#mmc1){ref-type="supplementary-material"}, and [S9](#mmc1){ref-type="supplementary-material"}). The product **2** was expected to be a side product due to the activities of JamA, C, and PKS without the action of JamB ([Figure 3](#fig3){ref-type="fig"}A). Other possible products were also analyzed, as it is conceivable that the PKSs accept different fatty acyl starter units *in vivo* via JamC or other acyl carriers ([Figure S10](#mmc1){ref-type="supplementary-material"}).Figure 3*In Vivo* Assessment of Alkyne-Tagged Polyketide Biosynthesis Using LipPKS1∗(A) Overview scheme of *in vivo* reactions between JamABC and LipPKS1∗ to produce 3-hydroxy-7-octynoic acid (**1**) and 3-hydroxy-7-octenoic acid (**2**).(B) Quantification of alkyne product titers resulting from the engineered JamC and LipPKS1∗. Alkyne **1** product titers are shown in blue (left y axis), and the relative JamB activities are shown in green (right y axis).(C) Quantification of total product titers resulting from the engineered JamC and LipPKS1∗. LipPKS1∗ cartoon is truncated for clarity. All titers shown have subtracted background from a control strain lacking JamC to better reflect the interaction between JamC and LipPKS1∗. All error bars represent SEM for n ≥ 3 biological replicates.

An initial investigation of the titer of compound **1** produced by the co-expression of JamA, B, C, and LipPKS1∗/DEBSM6∗ demonstrated that DEBSM6∗ produced compound **1** (0.014 mg/L) significantly less than LipPKS1∗ (0.071 mg/L). Much higher amounts of products other than **1** and **2** with a longer acyl chain were generated by DEBSM6∗ *in vivo* ([Figure S10](#mmc1){ref-type="supplementary-material"}), consistent with the native acyl chain length accepted by LipPKS1∗/DEBSM6∗ (C4 versus C13). We concluded that DEBSM6∗ would not be an effective *in vivo* model system to probe the activity of JamB due to complicated product profiles and thus limited the *in vivo* study to LipPKS1∗.

The products **1** and **2** were produced by LipPKS1∗ in an approximately 1:5 ratio, and this efficiency was set to be a relative JamB activity of 100% ([Figure 3](#fig3){ref-type="fig"}B). This product ratio was dropped ∼4-fold when either docking pair was used, suggesting that the fusion of a docking domain to JamC affected its recognition by JamB ([Figure 3](#fig3){ref-type="fig"}B). In contrast, the E32T point mutation of JamC had minimal effect on the product ratio while increasing the titer of **1** ∼6-fold to 0.42 mg/L, consistent with previous observations that the helix I of ACP did not play an important role in interacting with JamB ([@bib43], [@bib55]). We next probed the combined product titer of alkyne **1** and alkene **2** to assess the effectiveness of the two engineering strategies in their ability to improve JamC-LipPKS1∗ interactions *in vivo* ([Figure 3](#fig3){ref-type="fig"}C). Consistent with the trends observed *in vitro*, the combined titer improved more than 10- and 20-fold using docking domains ~C~dd^CurK^/~N~dd^CurL^ and ~C~dd^JamK^/~N~dd^JamL^, respectively, and ∼10-fold using JamC (E32T), demonstrating the success of either strategy in improving JamC-PKS interactions *in vivo* ([Figure 3](#fig3){ref-type="fig"}C).

Finally, we probed the possible synergistic effects of the two engineering strategies in improving the alkyne-tagged polyketide biosynthesis *in vivo*. We observed additive effects when using docking domains and the JamC point mutation in improving JamC- LipPKS1∗ interactions. The combined titer of **1** and **2** roughly equaled the sum of that when either engineering strategy was used. The maximum amount of product obtained was ∼16 mg/L from JamC(E32T)-~C~dd^JamK^/~N~dd^JamL^-LipPKS1∗, an approximately 39-fold increase from unmodified JamC/LipPKS1∗ ([Figure 3](#fig3){ref-type="fig"}C). However, due to the expected disruption of JamB activity when the docking domain is fused to JamC, the absolute titer of the alkyne product **1** was not increased when using both engineering strategies compared with the JamC mutagenesis alone ([Figure 3](#fig3){ref-type="fig"}B). These results further highlight the importance of JamB efficiency in *de novo* alkyne synthesis, which remains to be a limiting step in the production of alkyne-tagged polyketides.

Limitations of the Study {#sec2.5}
------------------------

Although the current results demonstrate a great potential of *de novo* biosynthesizing alkyne-tagged polyketides by engineering both the alkyne biosynthetic machinery and modular type I PKSs, the strategy is limited to incorporate an alkynyl starter unit, which needs to be tolerated by PKSs. It is expected to work well with PKSs with a native starter unit resembling the alkyne-containing acyl group presented by the alkyne biosynthetic machinery, such as in the case of LipPKS1, but may not work with PKSs recognizing very different starter units, such as in the case of DEBSM6. This is particularly exemplified by the *in vivo* results of DEBSM6, in which a complex metabolic background significantly decreased the efficiency of alkyne-tagged polyketide biosynthesis by these PKSs.

Conclusion {#sec2.6}
----------

We have successfully demonstrated that carrier protein-dependent alkyne biosynthetic machinery can work as a *trans* loading system for truncated Type I PKSs to produce alkyne-tagged polyketides both *in vitro* and *in vivo*. Two protein engineering strategies were explored to improve the interaction between the carrier protein within the alkyne biosynthetic machinery (JamC) and modular PKSs. This included the employment of PKS docking domains and site-directed mutagenesis of JamC to increase acyl chain translocation specificity. Both strategies were shown to be successful, leading to enhanced recognition of JamC by modular PKSs and thus improved alkyne-tagged polyketide production. In addition, the effects of both engineering strategies to improve protein-protein interactions were additive, leading to an ∼39-fold increase in the polyketide production by an engineered LipPKS1 in *E. coli*. It is also notable that the installation of a docking domain on JamC, but not the site-directed mutagenesis, disrupted its recognition by JamB in alkyne-tagged polyketide production. Furthermore, the native acyl group specificity of modular PKSs was suggested to be important for alkyne-tagged polyketide production, in particular *in vivo* where competing acyl groups were present. In summary, this work has shown the first examples of *de novo* biosynthesis of alkyne-tagged polyketides by modular type I PKSs through starter unit engineering and further provided engineering guidelines and strategies that are expected to be applicable to other modular PKSs to produce targeted alkyne-tagged metabolites for drug discovery and chemical biology studies.

Methods {#sec3}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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Document S1. Transparent Methods, Figures S1--S10, Scheme S1, and Tables S1 and S2
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